Haemonetics Corp (HAE) Stock Price, Quote & News

Company Profile

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLy...

Industry: Medical Devices

Sector: Healthcare

Phone: 781 848 7100

Website: www.haemonetics.com

Address:

125 Summer Street, Boston, United States

d_risk May. 21 at 9:49 AM

$HAE - Haemonetics Corporation - 10K - Updated Risk Factors Risk shifts highlight new concentration (a single customer now 13% of net revenue), execution risk from a major global ERP rollout, added regulatory burden and uncertainty from FDA’s new QMSR and evolving Brexit/Swexit rules, plus clarified but still evolving global tax exposure despite OBBBA and G7 Pillar Two relief. #MedicalDevices #CustomerConcentration #ERPImplementationRisk #RegulatoryCompliance #GlobalTaxExposure 🟢 Added 🟠 Removed https://d-risk.ai/HAE/10-K/2026-05-20

0 · Reply

SuperGreenToday May. 20 at 12:52 AM

$HAE Share Price: $56.85 Contract Selected: Dec 18, 2026 $70 Calls Buy Zone: $1.66 – $2.05 Target Zone: $3.03 – $3.70 Potential Upside: 73% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Cutlass May. 13 at 7:11 PM

$HAE Trim a tad for 9%+ 🟢

0 · Reply

Cutlass May. 12 at 2:35 PM

$HAE Bounced off 51....hmmmm 💰

1 · Reply

BillionerOfKing May. 11 at 5:27 PM

$HAE Current Stock Price: $52.76 Contracts to trade: $55.0 HAE May 15 2026 Call Entry: $0.10 Exit: $0.13 ROI: 35% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

MarketBeat May. 10 at 7:05 PM

https://marketbeat.com/a/8646178/ $HAE Haemonetics Q4 Earnings Call Highlights

0 · Reply

Observer1987 May. 10 at 5:30 PM

$HAE started with a small position at 52. Looking to add much more, don’t see a reason why this should be <60.

0 · Reply

Cutlass May. 8 at 3:22 PM

$HAE 👍

0 · Reply

Cutlass May. 8 at 2:22 PM

$HAE Dipped my toe in 51.78 on gap fill to start - Load zone 44 - 52 as noted 👀✍️⏰

0 · Reply

StocktwitsEarnings May. 7 at 10:16 AM

$HAE Q4 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.44 down -137.61% YoY • Reported revenue of $346.35M up 4.76% YoY • Haemonetics expects fiscal 2027 reported revenue growth of 4-7% and organic revenue growth of 3-6%. The company anticipates adjusted operating margin expansion of 50-100 bps and free cash flow conversion of approximately 80%.

0 · Reply

Haemonetics price target raised to $70 from $64 at Citi

2026-05-22T10:20:08.000Z - 6 days ago

Haemonetics upgraded to Buy at BofA on upside to guidance

2026-05-22T10:14:44.000Z - 6 days ago

Haemonetics upgraded to Buy from Neutral at BofA

May 12, 2026, 11:00 AM EDT - 15 days ago

Haemonetics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T11:46:56.000Z - 16 days ago

Haemonetics price target lowered to $89 from $94 at Barrington

May 10, 2026, 3:05 PM EDT - 17 days ago

Haemonetics Q4 Earnings Call Highlights

2026-05-08T16:35:30.000Z - 19 days ago

Haemonetics price target lowered to $67 from $72 at Baird

2026-05-08T12:22:46.000Z - 20 days ago

Haemonetics price target lowered to $62 from $74 at JPMorgan

May 7, 2026, 8:00 AM EDT - 21 days ago

Haemonetics Earnings Call Transcript: Q4 2026

May 7, 2026, 8:00 AM EDT - 21 days ago

Haemonetics Earnings release: Q4 2026

May 7, 2026, 8:00 AM EDT - 21 days ago

Haemonetics Slides: Q4 2026

May 7, 2026, 8:00 AM EDT - 21 days ago

Haemonetics Annual report: Q4 2026

2026-05-07T11:23:34.000Z - 21 days ago

Haemonetics reports Q4 adjusted EPS $1.29, consensus $1.27

2026-05-07T11:22:20.000Z - 21 days ago

Haemonetics sees FY27 adjusted EPS up 4%-7%

May 7, 2026, 6:00 AM EDT - 21 days ago

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

May 5, 2026, 6:00 AM EDT - 23 days ago

Haemonetics to Present at Bank of America 2026 Healthcare Conference

Apr 24, 2026, 6:20 AM EDT - 4 weeks ago

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

2026-04-13T14:47:50.000Z - 6 weeks ago

Haemonetics price target lowered to $70 from $80 at Mizuho

2026-04-13T12:05:19.000Z - 6 weeks ago

Haemonetics price target lowered to $84 from $88 at BTIG

2026-04-07T11:01:04.000Z - 7 weeks ago

Haemonetics price target lowered to $64 from $70 at Citi

Apr 1, 2026, 4:05 PM EDT - 2 months ago

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026

2026-03-30T20:17:51.000Z - 2 months ago

Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system

Mar 30, 2026, 4:15 PM EDT - 2 months ago

Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System

2026-03-11T09:26:19.000Z - 2 months ago

Haemonetics price target lowered to $70 from $75 at Citi

Mar 2, 2026, 10:25 AM EST - 3 months ago

Haemonetics Transcript: 47th Annual Raymond James Institutional Investor Conference

2026-02-23T21:26:13.000Z - 3 months ago

Haemonetics receives FDA clearance for NexSys PCS Plasma Collection System

Feb 23, 2026, 4:15 PM EST - 3 months ago

Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology

Feb 20, 2026, 4:05 PM EST - 3 months ago

Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference

2026-02-06T14:50:40.000Z - 3 months ago

Haemonetics price target lowered to $81 from $99 at Baird

2026-02-06T12:44:06.000Z - 3 months ago

Haemonetics price target lowered to $80 from $90 at Mizuho

2026-02-06T12:43:23.000Z - 3 months ago

Haemonetics price target raised to $94 from $93 at Barrington

2026-02-06T11:32:27.000Z - 3 months ago

Haemonetics price target lowered to $75 from $88 at Citi

Feb 5, 2026, 8:00 AM EST - 4 months ago

Haemonetics Earnings Call Transcript: Q3 2026

Feb 5, 2026, 8:00 AM EST - 4 months ago

Haemonetics Quarterly report: Q3 2026

Feb 5, 2026, 8:00 AM EST - 4 months ago

Haemonetics Earnings release: Q3 2026

Feb 5, 2026, 8:00 AM EST - 4 months ago

Haemonetics Slides: Q3 2026

2026-02-05T11:26:17.000Z - 4 months ago

Haemonetics reports Q3 adjusted EPS $1.31, consensus $1.25

2026-02-05T11:25:33.000Z - 4 months ago

Haemonetics narrows FY26 adjusted EPS view to $4.90-$5.00 from $4.80-$5.00

Feb 5, 2026, 6:00 AM EST - 4 months ago

Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Jan 13, 2026, 10:30 AM EST - 4 months ago

Haemonetics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 4 months ago

Haemonetics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 9:00 AM EST - 4 months ago

Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics

OBIO

Jan 9, 2026, 8:00 AM EST - 4 months ago

Vivasure Medical Announces Acquisition by Haemonetics Corporation

Jan 9, 2026, 6:15 AM EST - 4 months ago

Haemonetics Acquires Vivasure Medical Limited

Jan 7, 2026, 6:17 PM EST - 5 months ago

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026

Jan 2, 2026, 6:00 AM EST - 5 months ago

Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 30, 2025, 12:50 PM EST - 5 months ago

Earn Twice The Yield You Get From Bank On HAE Stock

Nov 6, 2025, 8:00 AM EST - 7 months ago

Haemonetics Earnings Call Transcript: Q2 2026

Nov 6, 2025, 8:00 AM EST - 7 months ago

Haemonetics Quarterly report: Q2 2026

Nov 6, 2025, 8:00 AM EST - 7 months ago

Haemonetics Earnings release: Q2 2026

Nov 6, 2025, 8:00 AM EST - 7 months ago

Haemonetics Slides: Q2 2026

Nov 6, 2025, 6:00 AM EST - 7 months ago

Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Oct 9, 2025, 4:05 PM EDT - 8 months ago

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Haemonetics Earnings Call Transcript: Q1 2026

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Haemonetics Quarterly report: Q1 2026

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Haemonetics Earnings release: Q1 2026

Aug 7, 2025, 6:00 AM EDT - 10 months ago

Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

Jul 9, 2025, 4:05 PM EDT - 11 months ago

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

Jun 9, 2025, 8:40 AM EDT - 1 year ago

Haemonetics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Haemonetics Proxy statement: Proxy Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Haemonetics Proxy statement: Proxy Filing

May 30, 2025, 6:00 AM EDT - 1 year ago

Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Haemonetics Earnings Call Transcript: Q4 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Haemonetics Annual report: Q4 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Haemonetics Earnings release: Q4 2025

May 8, 2025, 6:00 AM EDT - 1 year ago

Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

Mar 4, 2025, 2:50 PM EST - 1 year ago

Haemonetics Transcript: Raymond James & Associates’ 46th Annual Institutional Investors Conference 2025

Mar 3, 2025, 4:10 PM EST - 1 year ago

Haemonetics Announces Executive Leadership Updates

Feb 24, 2025, 6:00 AM EST - 1 year ago

Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference

Feb 6, 2025, 8:00 AM EST - 1 year ago

Haemonetics Earnings Call Transcript: Q3 2025

Feb 6, 2025, 8:00 AM EST - 1 year ago

Haemonetics Quarterly report: Q3 2025

Feb 6, 2025, 8:00 AM EST - 1 year ago

Haemonetics Earnings release: Q3 2025

Feb 6, 2025, 6:00 AM EST - 1 year ago

Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Jan 14, 2025, 8:15 PM EST - 1 year ago

Haemonetics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 8:15 PM EST - 1 year ago

Haemonetics Slides: FY 2025

Jan 14, 2025, 6:13 AM EST - 1 year ago

Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A

Jan 8, 2025, 5:03 PM EST - 1 year ago

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025

Jan 6, 2025, 6:00 AM EST - 1 year ago

Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 1:16 AM EST - 1 year ago

Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A

Nov 7, 2024, 8:00 AM EST - 1 year ago

Haemonetics Earnings Call Transcript: Q2 2025

Nov 7, 2024, 8:00 AM EST - 1 year ago

Haemonetics Quarterly report: Q2 2025

Nov 7, 2024, 8:00 AM EST - 1 year ago

Haemonetics Earnings release: Q2 2025

Nov 7, 2024, 6:00 AM EST - 1 year ago

Haemonetics 2nd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Oct 3, 2024, 4:05 PM EDT - 1 year ago

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024

Aug 15, 2024, 6:30 AM EDT - 1 year ago

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Haemonetics Earnings Call Transcript: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Haemonetics Quarterly report: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Haemonetics Earnings release: Q1 2025

Aug 8, 2024, 6:00 AM EDT - 1 year ago

Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Jul 30, 2024, 6:00 AM EDT - 1 year ago

Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire

Jul 8, 2024, 4:05 PM EDT - 2 years ago

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024

Jun 18, 2024, 4:15 PM EDT - 2 years ago

Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device

Jun 7, 2024, 8:00 AM EDT - 2 years ago

Haemonetics Proxy statement: Proxy Filing

Jun 7, 2024, 8:00 AM EDT - 2 years ago

Haemonetics Proxy statement: Proxy Filing

May 23, 2024, 6:00 AM EDT - 2 years ago

Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes

May 21, 2024, 4:05 PM EDT - 2 years ago

Haemonetics Announces Proposed Convertible Senior Notes Offering

May 9, 2024, 8:00 AM EDT - 2 years ago

Haemonetics Earnings Call Transcript: Q4 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Haemonetics Annual report: Q4 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Haemonetics Earnings release: Q4 2024

May 9, 2024, 6:00 AM EDT - 2 years ago

Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Apr 10, 2024, 4:58 PM EDT - 2 years ago

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024

Apr 4, 2024, 6:30 AM EDT - 2 years ago

Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Haemonetics Corporation Completes Acquisition of Attune Medical

Mar 5, 2024, 7:30 AM EST - 2 years ago

Haemonetics Transcript: 45th Annual Raymond James Institutional Investors Conference 2024

Mar 5, 2024, 6:00 AM EST - 2 years ago

Haemonetics Announces Definitive Agreement to Acquire Attune Medical

Feb 21, 2024, 5:57 PM EST - 2 years ago

Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference

Feb 21, 2024, 5:55 PM EST - 2 years ago

Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Feb 8, 2024, 8:00 AM EST - 2 years ago

Haemonetics Earnings Call Transcript: Q3 2024

Feb 8, 2024, 8:00 AM EST - 2 years ago

Haemonetics Quarterly report: Q3 2024

Feb 8, 2024, 8:00 AM EST - 2 years ago

Haemonetics Earnings release: Q3 2024

Feb 8, 2024, 6:00 AM EST - 2 years ago

Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Jan 11, 2024, 4:05 PM EST - 2 years ago

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024

Jan 9, 2024, 12:45 PM EST - 2 years ago

Haemonetics Transcript: J.P. Morgan 2024 42nd Annual Healthcare Conference

Jan 9, 2024, 12:45 PM EST - 2 years ago

Haemonetics Slides: FY 2024

Dec 12, 2023, 6:00 AM EST - 2 years ago

Haemonetics Corporation Completes Acquisition of OpSens Inc.

Dec 7, 2023, 4:05 PM EST - 2 years ago

Haemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Haemonetics Earnings Call Transcript: Q2 2024

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Haemonetics Quarterly report: Q2 2024

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Haemonetics Earnings release: Q2 2024

Nov 2, 2023, 6:00 AM EDT - 2 years ago

Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

d_risk May. 21 at 9:49 AM

0 · Reply

SuperGreenToday May. 20 at 12:52 AM

0 · Reply

Cutlass May. 13 at 7:11 PM

$HAE Trim a tad for 9%+ 🟢

0 · Reply

Cutlass May. 12 at 2:35 PM

$HAE Bounced off 51....hmmmm 💰

1 · Reply

BillionerOfKing May. 11 at 5:27 PM

0 · Reply

MarketBeat May. 10 at 7:05 PM

https://marketbeat.com/a/8646178/ $HAE Haemonetics Q4 Earnings Call Highlights

0 · Reply

Observer1987 May. 10 at 5:30 PM

$HAE started with a small position at 52. Looking to add much more, don’t see a reason why this should be <60.

0 · Reply

Cutlass May. 8 at 3:22 PM

$HAE 👍

0 · Reply

Cutlass May. 8 at 2:22 PM

$HAE Dipped my toe in 51.78 on gap fill to start - Load zone 44 - 52 as noted 👀✍️⏰

0 · Reply

StocktwitsEarnings May. 7 at 10:16 AM

0 · Reply

Cutlass May. 6 at 4:36 PM

$HAE Still waiting 😄

0 · Reply

Cutlass May. 1 at 7:21 PM

$HAE Not yet -

0 · Reply

Cutlass Apr. 24 at 3:21 PM

$HAE Patience - in time, in time 👀

0 · Reply

OfficialStocktwitsUser Apr. 8 at 8:57 PM

$HAE RSI: 50.04, MACD: -1.1586 Vol: 1.96, MA20: 57.97, MA50: 60.77 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Renecurtis Mar. 25 at 9:55 AM

$HAE almost there

0 · Reply

ZacksResearch Mar. 12 at 3:07 PM

$HAE down 7.7% compared to the industry's 17% decline — can the hospital business recovery save it? 📉 🏥 Strong Hospital recovery with Attune Medica and OpSens acquisitions 🔬 NexSys PCS system adoption driving margin expansion ⚠️ Watch out for debt concerns and competitive pressures Full analysis here 👉 https://www.zacks.com/stock/news/2883093/is-it-apt-to-retain-haemonetics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2883093-body-37153&ADID=SYND_STOCKTWITS_TWEET_2_2883093_BODY_37153

0 · Reply

ZacksResearch Mar. 12 at 2:07 PM

$HAE showing growth signals — but the risk side of the story isn’t going away. ⚠️ NexSys PCS adoption and hospital recovery point to potential growth ahead, yet a leveraged balance sheet and stiff competition continue to cloud the company’s outlook. See the full risk/reward breakdown 👉 https://www.zacks.com/stock/news/2883093/is-it-apt-to-retain-haemonetics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2883093-teaser-37151&ADID=SYND_STOCKTWITS_TWEET_2_2883093_TEASER_37151

0 · Reply

Cutlass Mar. 11 at 4:07 PM

$HAE Come on down !

0 · Reply

TechridyStocks Mar. 3 at 4:32 PM

$HAE very strong

0 · Reply

SuperGreenToday Mar. 3 at 2:40 PM

$HAE Share Price: $62.55 Contract Selected: Sep 18, 2026 $70 Calls Buy Zone: $8.25 – $10.20 Target Zone: $13.24 – $16.18 Potential Upside: 51% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Estimize Feb. 27 at 12:03 AM

Wall St is expecting 1.27 EPS for $HAE Q4 [Reporting 05/07 BMO] http://www.estimize.com/intro/hae?chart=historical&metric_name=eps&utm_cont

0 · Reply

Market Cap	3.04B
Revenue (ttm)	1.33B
Net Income (ttm)	97.31M
EPS (ttm)	N/A
PE Ratio	13.18
Forward PE	12.52
Profit Margin	7.29%
Debt to Equity Ratio	1.53

Volume	1,138,200
Avg Vol	804,378
Day's Range	N/A - N/A
Shares Out	45.45M
Stochastic %K	96%
Beta	0.53
Analysts	Strong Sell
Price Target	$81.00